JCRRF (JCR Pharmaceuticals Co) Beneish M-Score: -2.55 (As of Jun. 26, 2026)


JCRRF JCR Pharmaceuticals Co Ltd JCRRF
65 GF Score
Price $3.15
GF Value $4.97
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is JCR Pharmaceuticals Co Beneish M-Score?

JCR Pharmaceuticals Co JCRRF 65 Beneish M-Score is -2.55 as of Jun. 26, 2026. GuruFocus rates JCRRF with a GF Score™ of 65/100 and a GF Value™ of $4.97 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 911 Drug Manufacturers companies, JCR Pharmaceuticals Co ranks better than 54.56% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.55 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for JCR Pharmaceuticals Co's Beneish M-Score or its related term are showing as below:

JCRRF' s Beneish M-Score Range Over the Past 10 Years
Min: -2.83   Med: -2.47   Max: -1.57
Current: -2.55

During the past 13 years, the highest Beneish M-Score of JCR Pharmaceuticals Co was -1.57. The lowest was -2.83. And the median was -2.47.


JCR Pharmaceuticals Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for JCR Pharmaceuticals Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JCR Pharmaceuticals Co Beneish M-Score Chart

JCR Pharmaceuticals Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.57 -1.85 -2.43 -2.55 0.00

JCR Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.55 0.00 0.00 0.00 0.00

JCRRF vs LLY, JNJ, ABBV: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JCR Pharmaceuticals Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where JCR Pharmaceuticals Co's Beneish M-Score falls into.


JCRRF
65GF Score
JCR Pharmaceuticals Co Ltd JCRRF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JCR Pharmaceuticals Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of JCR Pharmaceuticals Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0621+0.528 * 1.109+0.404 * 1.094+0.892 * 0.7754+0.115 * 1.1627
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * 0.006934-0.327 * 1.2281
=-2.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Total Receivables was $82.1 Mil.
Revenue was $221.9 Mil.
Gross Profit was $145.8 Mil.
Total Current Assets was $342.5 Mil.
Total Assets was $703.5 Mil.
Property, Plant and Equipment(Net PPE) was $251.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $22.6 Mil.
Selling, General, & Admin. Expense(SGA) was $0.0 Mil.
Total Current Liabilities was $295.1 Mil.
Long-Term Debt & Capital Lease Obligation was $80.8 Mil.
Net Income was $-31.9 Mil.
Gross Profit was $0.0 Mil.
Cash Flow from Operations was $-36.8 Mil.
Total Receivables was $99.7 Mil.
Revenue was $286.2 Mil.
Gross Profit was $208.6 Mil.
Total Current Assets was $384.3 Mil.
Total Assets was $682.3 Mil.
Property, Plant and Equipment(Net PPE) was $200.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $21.3 Mil.
Selling, General, & Admin. Expense(SGA) was $0.0 Mil.
Total Current Liabilities was $201.1 Mil.
Long-Term Debt & Capital Lease Obligation was $95.8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(82.089 / 221.874) / (99.681 / 286.153)
=0.36998 / 0.348349
=1.0621

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(208.592 / 286.153) / (145.836 / 221.874)
=0.728953 / 0.657292
=1.109

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (342.525 + 250.977) / 703.453) / (1 - (384.338 + 200.509) / 682.332)
=0.156302 / 0.14287
=1.094

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=221.874 / 286.153
=0.7754

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(21.339 / (21.339 + 200.509)) / (22.636 / (22.636 + 250.977))
=0.096187 / 0.08273
=1.1627

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 221.874) / (0 / 286.153)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((80.841 + 295.107) / 703.453) / ((95.782 + 201.143) / 682.332)
=0.534432 / 0.435162
=1.2281

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-31.927 - 0 - -36.805) / 703.453
=0.006934

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

JCR Pharmaceuticals Co has a M-score of -2.55 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.55 mean?
JCR Pharmaceuticals Co (JCRRF) has a Beneish M-Score of -2.55 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on JCR Pharmaceuticals Co and its competitors. According to the industry distribution chart, JCR Pharmaceuticals Co ranks #414 out of 911 companies in the Drug Manufacturers industry, placing it in the top 45.4%.
Is JCR Pharmaceuticals Co's Beneish M-Score too high?
JCR Pharmaceuticals Co's current Beneish M-Score is -2.55. Based on the distribution chart, JCR Pharmaceuticals Co ranks #414 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, JCR Pharmaceuticals Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JCR Pharmaceuticals Co's Beneish M-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, JCR Pharmaceuticals Co ranks #414 out of 911 companies for Beneish M-Score. This puts JCR Pharmaceuticals Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on JCR Pharmaceuticals Co and its competitors. JCR Pharmaceuticals Co's current Beneish M-Score is -2.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JCR Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co (JCRRF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.97, compared to a current price of $3.15 — trading 36.7% below its estimated fair value. The current Beneish M-Score is -2.55. JCR Pharmaceuticals Co's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For JCR Pharmaceuticals Co (JCRRF), the current Beneish M-Score is -2.55 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JCR Pharmaceuticals Co (JCRRF) Overvalued in 2026?

Based on GuruFocus' analysis, JCR Pharmaceuticals Co stock appears to be undervalued. The current stock price of $3.15 is trading 36.7% below its estimated GF Value™ of $4.97. GuruFocus considers JCR Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for JCRRF:

  • Beneish M-Score: -2.55
  • GF Value™: $4.97 vs. price of $3.15 (36.7% below fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the JCRRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


JCR Pharmaceuticals Co Business Description

Other Exchanges 4552:Japan
Address 3-19 Kasuga-cho, Ashiya, Hyogo, JPN, 659-0021
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
65GF Score

Get the complete analysis for JCRRF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.15
Price
$4.97
GF Value